Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:SMLR 24 October 2025 - 5 January 2026

Strive Asset Management (ASST) stock jumps premarket as Bitcoin firms and Semler vote looms

Strive Asset Management (ASST) stock jumps premarket as Bitcoin firms and Semler vote looms

ASST shares rose about 10% in early premarket trading Monday, following a 17% gain Friday and heavy volume. Bitcoin held above $92,000, supporting crypto-linked stocks, with Strategy and Semler Scientific also higher. Investors are watching for a shareholder vote on Strive’s proposed all-stock acquisition of Semler Scientific. Traders eye $0.75 as support and $0.90–$1 as resistance for ASST.
5 January 2026
···
Strive Asset Management Stock (ASST): Bitcoin Treasury High‑Flyer Under Pressure – Latest News, Analysis and 2026 Outlook

Strive Asset Management Stock (ASST): Bitcoin Treasury High‑Flyer Under Pressure – Latest News, Analysis and 2026 Outlook

Strive, Inc. (Nasdaq: ASST) traded at about $0.90 per share in early December 2025, down 8% on the day and over 40% for the month. The company holds more than 7,500 Bitcoin and is pursuing an all-stock merger with Semler Scientific. Strive’s market cap stands near $740 million, with volatility underscored by a beta of 17.4. The firm faces a public dispute with MSCI over Bitcoin-focused companies’ index inclusion.
8 December 2025
···
Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive Asset Management (ASST) prices upsized 12% preferred stock IPO to raise ~$160M; fresh Semler (SMLR) merger filing lands — Nov. 6, 2025

Strive, Inc. priced an upsized offering of 2 million shares of its SATA preferred stock at $80 each, targeting $160 million in gross proceeds. The stock carries a 12% initial annual dividend and may fund Bitcoin purchases, among other uses. Semler Scientific filed an 8-K confirming Strive’s recent capital moves and Bitcoin holdings as their pending merger advances. Settlement is set for November 10, 2025.
6 November 2025
···
Strive (ASST) Stock Skyrockets 40% on Bitcoin Bet – Wild Rally Spurs Bold Forecasts

Strive (ASST) Stock Skyrockets 40% on Bitcoin Bet – Wild Rally Spurs Bold Forecasts

Strive Asset Management (NASDAQ: ASST) surged as much as 40% overnight into Oct. 27, 2025, after a 27% spike Friday, trading around $1.37 pre-market. The rally follows Bitcoin’s rebound above $115,000 and Strive’s $1.34 billion merger to acquire Semler Scientific, boosting its Bitcoin holdings to nearly 11,000 BTC. ASST remains volatile, still down 90% from its mid-2025 peak. No major Wall Street firm covers the stock.
27 October 2025
··
Strive’s Bitcoin Bonanza: $1.3B Merger, 11K BTC and a Wild Stock Ride

Strive (ASST) Stock Skyrockets on Bitcoin Boom – Inside the Wild Rally

Strive (NASDAQ: ASST) jumped up to 40% overnight into Monday, building on Friday’s 27% surge to close at $1.10. The Dallas-based company, now holding nearly 11,000 Bitcoin after a $1.34 billion merger with Semler Scientific, has gained 124% year-to-date. Bitcoin’s rally above $115,000 fueled the stock’s rise. ASST remains highly volatile, still down about 90% from its 2025 peak.
27 October 2025
···
ASST Stock Surges on Bitcoin Deals – Strive’s Bold Strategy Explained

ASST Stock Surges on Bitcoin Deals – Strive’s Bold Strategy Explained

Strive Asset Management (ASST) closed at $1.10 on Oct. 24, up 27.3% on heavy volume, after announcing major Bitcoin acquisitions and mergers. The Dallas-based firm will merge with Semler Scientific in an all-stock deal and buy True North Inc., adding over 10,900 BTC to its treasury. Strive also raised $750 million in May to fund Bitcoin purchases and named Ben Werkman as Chief Investment Officer.
24 October 2025
·····

Stock Market Today

  • Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate
    April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow projections turning positive by 2026. However, actual cash flow remains negative at $501.5 million last year. Investors must weigh DCF optimism against market risks and sector volatility. Ultragenyx scores 4 out of 6 in valuation, indicating some appeal but highlighting areas needing scrutiny.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 2:08 AM EDT Ultragenyx Pharmaceutical Shares Surge 8.1% Weekly Amid Valuation Debate April 9, 2026, 2:08 AM EDT. Ultragenyx Pharmaceutical (RARE) shares rose 8.1% last week to $23.15 amid mixed performance, down 1.9% year-to-date and 31.7% over 12 months. The biotech specializes in rare disease treatments, a sector sensitive to clinical trial and regulatory updates. Despite recent gains, the company's long-term returns remain negative. A discounted cash flow (DCF) analysis values Ultragenyx at about $257.43 per share, suggesting it is 91% undervalued based on future free cash flow
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Go toTop